Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Exaluren · ELX-02, NB-124

Small molecule · developed by Eloxx Pharmaceuticals

Phase 2 Most advanced trial

ELOX Developer

2 Registered trials

What is Exaluren?

Exaluren is a synthetic eukaryotic ribosome selective glycoside (ERSG), a small molecule developed for genetic diseases caused by nonsense mutations. It is being studied in Alport syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ELX-02, NB-124
Drug type: Small molecule
Pathways: nonsense mutation readthrough
Therapy area: Renal & urology
Developer: Eloxx Pharmaceuticals, Inc. (ELOX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: TP732M43NA

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07523581	Phase 2	Alport Syndrome, X-Linked	Recruiting	ELOX
NCT05448755	Phase 2	Alport Syndrome	Completed	ELOX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alport Syndrome, Autosomal RecessiveAlport Syndrome, X-LinkedAlport Syndrome

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ELOX page.

Follow ELOX, the company behind Exaluren

See ELOX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ELOX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z